Genzyme Corp.

ACTIVE

马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.sanofigenzyme.com/enSubsidiary10,100 employees

Part of sanofi-aventis sa

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

62.5%

Phase 3

25.0%

Phase 2

12.5%

Trial Status Distribution

Active, not recruiting

25.0%

Recruiting

75.0%

Clinical Trials

Trials sponsored by this organization (8)

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS)

Phase 1

Recruiting

interventional

Jun 2024849 participants

Fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B

Phase 1

Active, not recruiting

interventional

May 202432 participants

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Phase 1

Recruiting

interventional

Mar 202469 participants

ong-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX

Phase 1

Active, not recruiting

interventional

Feb 2024281 participants

Venglustat in Combination with Cerezyme in Adult Patients with Gaucher Disease Type 3 withvenglustat monotherapy extensio

Phase 1

Recruiting

interventional

Nov 202318 participants

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Phase 3

Recruiting

23 participants

Venglustat in Combination with Cerezyme in Adult Patients with Gaucher Disease Type 3 with venglustat monotherapy extension

Phase 2

Recruiting

3 participants

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS)

Phase 3

Recruiting

487 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations